Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00824434




Registration number
NCT00824434
Ethics application status
Date submitted
15/01/2009
Date registered
16/01/2009
Date last updated
30/08/2012

Titles & IDs
Public title
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Scientific title
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Secondary ID [1] 0 0
S2051
Universal Trial Number (UTN)
Trial acronym
PLATINUM QCA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atherosclerosis 0 0
Coronary Artery Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - PROMUS Element™

Experimental: Experimental Stent -


Treatment: Devices: PROMUS Element™
Drug eluting coronary stent system
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Cardiac Events (Composite)
Timepoint [1] 0 0
30 days
Secondary outcome [1] 0 0
In-stent Late Loss
Timepoint [1] 0 0
9 months
Secondary outcome [2] 0 0
Occurance of Post-procedure Incomplete Stent Apposition
Timepoint [2] 0 0
Post-procedure
Secondary outcome [3] 0 0
Myocardial Infarction (MI)
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
All-cause Mortality
Timepoint [4] 0 0
12 months
Secondary outcome [5] 0 0
Target Lesion Revascularization (TLR)
Timepoint [5] 0 0
30 Days
Secondary outcome [6] 0 0
Target Lesion Revascularization (TLR)
Timepoint [6] 0 0
12 Months
Secondary outcome [7] 0 0
Target Vessel Revascularization (TVR)
Timepoint [7] 0 0
30 Days
Secondary outcome [8] 0 0
Target Vessel Revascularization (TVR)
Timepoint [8] 0 0
12 months
Secondary outcome [9] 0 0
Target Lesion Failure (TLF)
Timepoint [9] 0 0
12 months
Secondary outcome [10] 0 0
Target Vessel Failure (TVF)
Timepoint [10] 0 0
12 months
Secondary outcome [11] 0 0
Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition
Timepoint [11] 0 0
24 hours
Secondary outcome [12] 0 0
Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition
Timepoint [12] 0 0
>24 hr-30 days
Secondary outcome [13] 0 0
Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition
Timepoint [13] 0 0
>30 days-1 year
Secondary outcome [14] 0 0
Clinical Procedural Success
Timepoint [14] 0 0
Duration of hospital stay (usually 1-2 days)
Secondary outcome [15] 0 0
Technical Success
Timepoint [15] 0 0
Acute-At time of index procedure

Eligibility
Key inclusion criteria
* Patient (or legal guardian) understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
* Patient is eligible for percutaneous coronary intervention (PCI)
* Patient has documented stable angina pectoris (Canadian Cardiovascular Society [CCS] Classification 1, 2, 3, or 4) or documented silent ischemia; or unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C)
* Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
* Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
* Patient is willing to comply with all specified follow-up evaluations

Angiographic

* Target lesion must be a de novo lesion located in a native coronary artery with visually estimated diameter of >=2.25 mm and <=4.25 mm
* Target lesion length must measure (by visual estimate) <=34 mm
* Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
* Patient has had a known diagnosis of recent MI (within 30 days prior to the index procedure) and has elevated enzymes at the time of the index procedure as follows.

* Patients are excluded if any of the following criteria are met at the time of the index procedure

* If creatine kinase, MB band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of the creatine kinase (CK) Total.
* If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
* If CK Total/CK-MB are not used and Troponin is, the patients are excluded if the following criterion is met at the time of the index procedure.

* Troponin >1× ULN with at least one of the following.

* Patient has ischemic symptoms and electrocardiogram (ECG) changes indicative of ongoing ischemia (e.g., >1mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
* Development of pathological Q-waves in the ECG
* Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Note: For patients who have had a recent MI, CK Total/CK-MB (or Troponin if CK Total/CK-MB are not used) must be documented prior to enrolling the patient

* Patient has received an organ transplant or is on a waiting list for an organ
* transplant
* Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
* Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
* Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
* Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
* Patient has a white blood cell (WBC) count <3,000 cells/mm3
* Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
* Patient is on dialysis or has known renal insufficiency (i.e., estimated creatinine clearance <50 mL/min by the Cockcroft Gault formula, ie [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dL)*72])
* Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
* Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
* Target vessel or side branch has been treated with any type of percutaneous coronary intervention (PCI; eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure
* Target vessel has been treated within 10 mm proximal or distal to the target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to the index procedure
* Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index procedure
* Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
* Planned percutaneous coronary intervention or coronary artery bypass grafting after the index procedure
* Patient previously treated at any time with coronary intravascular brachytherapy
* Patient has a known allergy to the study stent system or protocol-required concomitant medications (e.g., stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
* Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
* Patient has one of the following:

* Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months
* Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
* Planned procedure that may cause non-compliance with the protocol or confound data interpretation
* Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
* Patient intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
* Known intention to procreate within 12 months after the index procedure
* Female with positive pregnancy test within 7 days prior to the index procedure (a pregnancy test must be performed in women of child-bearing potential prior to enrollment), or lactating
* Patient has more than 1 target lesion or more than 1 target lesion and 1 non-target lesion, identified during screening for intervention

Angiographic

* Target lesion meets any of the following criteria:

* Aorto-ostial location (i.e., lesion located within 5 mm of the ostium)
* Left main location
* Located within 5 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery
* Located within a saphenous vein graft or an arterial graft
* Can only be accessed via a saphenous vein graft or an arterial graft
* Involves a side branch >=2.0 mm in diameter
* Involves a clinically significant side branch <2.0 mm in diameter that has a clinically significant stenosis at the ostium
* TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing
* Excessive tortuosity proximal to or within the lesion
* Extreme angulation proximal to or within the lesion
* Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified
* Restenotic from previous intervention
* Thrombus, or possible thrombus, present in the target vessel
* Patient has an additional clinically significant lesion(s) in the target vessel for which an intervention within 12 months after the index procedure is likely to be required

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2010
Sample size
Target
Accrual to date
Final
100
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
St. Vincent's Hospital - Sydney - Darlinghurst
Recruitment hospital [2] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [4] 0 0
St. Vincent Hospital (Melbourne) - Fitzroy
Recruitment hospital [5] 0 0
Fremantle Hospital - Fremantle
Recruitment hospital [6] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [7] 0 0
The Prince Charles Hospital - Brisbane
Recruitment hospital [8] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [9] 0 0
Sir Charles Gairdner Hospital - Perth
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment postcode(s) [5] 0 0
6160 - Fremantle
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
4032 - Brisbane
Recruitment postcode(s) [8] 0 0
2170 - Liverpool
Recruitment postcode(s) [9] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
Malaysia
State/province [1] 0 0
Kuala Lumpur
Country [2] 0 0
New Zealand
State/province [2] 0 0
Auckland
Country [3] 0 0
New Zealand
State/province [3] 0 0
Christchurch
Country [4] 0 0
New Zealand
State/province [4] 0 0
Dunedin
Country [5] 0 0
New Zealand
State/province [5] 0 0
Wellington
Country [6] 0 0
Singapore
State/province [6] 0 0
Singapore

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boston Scientific Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo atherosclerotic lesion
Trial website
https://clinicaltrials.gov/study/NCT00824434
Trial related presentations / publications
Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW, Teirstein PS, Starzyk RM, Allocco DJ, Dawkins KD. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention. 2011 May;7(1):84-90. doi: 10.4244/EIJV7I1A15.
Public notes

Contacts
Principal investigator
Name 0 0
Ian T. Meredith, MBBS
Address 0 0
Monash Medical Centre
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00824434